DXCM
USDDexCom Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$61.090
High
$62.390
Low
$58.880
Volume
8.96M
Company Fundamentals
Market Cap
23.9B
Industry
Medical devices
Country
United States
Trading Stats
Avg Volume
5.54M
Exchange
NMS
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Nov 4, 2025DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?
Market Pulse Check
- Current Price: $60.43 (as of 2025-11-03 close)
- Recent Swing: +3.8% rebound after 61% decline since August highs
- Key Technicals: MACD bearish crossover vs. surging 19x average volume
Price Action Breakdown
- August-Sept Stability: Traded $75-$82 range
- Sept 19 Crash: -11% drop on 3x average volume
- October Freefall: 35% decline accelerated by legal news
- November Lifeline: +3.8% gain on massive 17.8M shares traded
News Impact Matrix
| Sentiment | Count | Key Developments |
|---|---|---|
| Negative | 9 | 6 law firm investigations filed |
| Analyst Mixed | 12 | 8 lowered PTs (range $75-$99) |
| Positive | 1 | New board member appointment |
AI Forecast Snapshot
| Timeframe | Prediction | Notes |
|---|---|---|
| 1-day | -0.8% | Potential pullback after surge |
| 2-day | +1.6% | Technical rebound potential |
| 3-day | +1.9% | Resistance near $62 area |
Strategic Considerations
For Active Traders:
- Watch $61.15 breakout level (Nov 3 high)
- Consider partial profits at $62.90 TP
- Hard stop below $58.50 support
Long-term Investors:
- Monitor lawsuit developments closely
- Debt concerns (94% D/E ratio) require scrutiny
- Potential accumulation zone if $58 holds
Bottom Line
DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.
This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.
Related News
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...
UBS Maintains Buy on DexCom, Lowers Price Target to $95
UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...
Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93
Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.
AI PredictionBeta
AI Recommendation
Updated at: Nov 4, 2025, 09:09 PM
60.6% Confidence
Risk & Trading
Entry Point
$58.80
Take Profit
$62.91
Stop Loss
$52.39
Key Factors
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.